

ACADEMIC ACTIVITIES

Publication of the week

1. Lin, X., Lei, V. L. C., Li, D., and Yuan, Z. (2018) Which is more costly in Chinese to English simultaneous interpreting, "pairing" or "transphrasing"? Evidence from an fNIRS neuroimaging study. *Neurophotonics* 5, 025010
2. Wang, X., Ge, W., and Zhang, Y. (2018) Recombinant DHX33 Protein Possesses Dual DNA/RNA Helicase Activity. *Biochemistry*
3. Zhang, Y., Long, X., Ma, X., He, Q., Luo, X., Bian, Y., Xi, Y., Sun, X., Ng, C. H., Vieta, E., and Xiang, Y. T. (2018) Psychometric properties of the Chinese version of the Functioning Assessment Short Test (FAST) in bipolar disorder. *J Affect Disord* 238, 156-160
4. Sun, S., Jin, Y., Chen, C., Sun, B., Cao, Z., Lo, I. L., Zhao, Q., Zheng, J., Shi, Y., and Zhang, X. D. (2018) Entropy Change of Biological Dynamics in Asthmatic Patients and Its Diagnostic Value in Individualized Treatment: A Systematic Review. *Entropy* 20(6), 402
5. Li, S., Gaur, U., Chong, C. M., Lin, S., Fang, J., Zeng, Z., Wang, H., and Zheng, W. (2018) Berberine Protects Human Retinal Pigment Epithelial Cells from Hydrogen Peroxide-Induced Oxidative Damage through Activation of AMPK. *Int J Mol Sci* 19

VISITS AND EVENTS

UM and Zhejiang University signed an agreement on medical professionals training and collaboration in Biomedical Research and Innovation

UM delegation led by Rector Yonghua SONG, recently visited Zhejiang University and signed an agreement on full collaboration in the field of Biomedical Sciences. As stipulated, FHS and School of Medicine of Zhejiang University (ZJUSM) will jointly launch a dual Bachelor degree programme in Science and Medicine and a postgraduate training programme that attract students from Macau and Zhejiang who are interested in pursuing a career in medicine and biomedical sciences. FHS and ZJUSM will also establish a collaborative centre for medical research that brings long-term mutual benefits to both parties in various aspects.



Prof. Ren-He Xu, our Associate Dean Research joined the visit.

PI INTRODUCTION SERIES

Prof. Hang Fai (Henry) KWOK

Prof. Hang Fai (Henry) KWOK obtained his first class B.Sc. (Hons) degree in Biotechnology and Ph.D. in Biomedical Sciences in the United Kingdom (UK). In 2007, he completed a period of postdoctoral training at Queen's University Belfast (QUB), the No.1 Pharmacy School in the UK, and in that year, he also won the Knowledge Transfer Partnerships (KTP) Northern Ireland Regional Award. He then moved to industry as Senior Scientist in a spinout company from QUB, Fusion Antibodies Limited, which was recently listed on the FTSE All-Share AIM index on the London Stock Exchange as Fusion Antibodies Plc. (FAB).




During his postdoctoral and industrial training, his work on proteins (antigens) and antibodies in the battle against infectious diseases and cancer contributed to four international patents as inventor and a number of Science Citation Index (SCI) publications as the first/corresponding author. He subsequently returned to academia in 2010 as a Senior Research Fellow in the Department of Oncology at the University of Cambridge, working with Prof. Gillian Murphy and Prof. John McCafferty at the Cancer Research UK (CRUK) Cambridge Institute and the Department of Biochemistry respectively, bringing together his interests in protease biochemistry research with biologics development to pursue novel therapeutic, prognostic and diagnostic approaches in the treatment of cancer and other diseases. As well as his protease and antibody research, Prof. KWOK also served as a visiting fellow in Prof. Chris Shaw's Natural Drug Discovery group in the School of Pharmacy, QUB from 2007 until 2017. This attachment focused on proteomic characterization of novel bioactive molecules from sources in nature including amphibian defensive skin secretions, and reptile, scorpion and insect venoms for exploiting their therapeutic potential. For all the above research, Prof. KWOK published a number of SCI papers including *Molecular Biology and Evolution* [IF: 14.558], *PNAS* [IF: 10.414], *Molecular & Cellular Proteomics* [IF: 6.540], *Molecular Cancer* [IF: 6.335] and *Human Molecular Genetics* [IF: 5.689].

Prof. KWOK joined FHS as Assistant Professor in March 2014. His first batch of Ph.D. students have already graduated in late 2017 and early 2018, and subsequently got the job offers from the Nanjing University of Chinese Medicine and the King's College London as lecturer and postdoctoral fellow respectively. Prof. KWOK's research group currently has 3 postdoctoral fellows and 4 Ph.D. students. His research interests mainly focus on the development of novel monoclonal antibodies and venom-based peptides as prototype drugs for anti-cancer and anti-inflammatory therapies. In addition, Prof. KWOK's research group is also expanding scientific knowledge and research in the areas of existing and novel cancer biomarkers such as 1) matricellular protein -- OPN, 2) metalloproteinase -- ADAM17 & ADAMTS5, 3) DNA replication licensing factor -- MCM proteins, 4) small GTP binding protein -- RAN, as well as immunotherapy markers (e.g. PD-1/PD-L1) in order to identify and validate their prognostic and therapeutic values according to the roles in hallmarks of cancer.

Since 2014, Prof. KWOK's research group in FHS has published over 40 SCI papers such as *Biochimica et Biophysica Acta (BBA) Reviews on Cancer* [IF: 9.452] and *Hypertension* [IF: 6.699]. In 2015, he authored two book chapters (Exendin Peptide and B-Type Natriuretic Peptide Therapies) which were published by the Oxford University Press [ISBN 978-0-19-930939-9]. Last year, Prof. KWOK also filed two U.S. provisional patents with the University of Macau entitled "Anti-ADAM17 antibody as an add-on therapy for hypertensive patients" and "Anti-ADAM17 antibody in pancreatic cancer treatment". Currently, he is working closely with the University to negotiate a potential licensing agreement with a biotechnology company in Mainland China.

As well as his assistant professorship at UM, Prof. KWOK is an internationally recognized academic who currently holds the title of Visiting Scientist in the CRUK Cambridge Institute at the University of Cambridge. To date, he has received six competitive research funding/grants in Macau, three of which have been fully completed with all objectives being met. Prof. KWOK's research is having considerable impact, indeed, his publications with the UM have thus far been cited 550 times since 2014. He is an active member of the Antibody Society, International Society on Toxinology, Biochemical Society and American Association for Cancer Research. In the last few years, Prof. KWOK has been invited to serve as Ph.D./M.Phil. External Examiner for the Monash University, the Queen's University Belfast and the University of Hong Kong. Following an invitation in 2017, Prof. KWOK is currently serving as Guest Editor for a special issue of *Toxins* titled "Venom and Toxin as Targeted Therapy". He has also been appointed as Editorial Board Member of a number of SCI journals including *Toxins* and *Recent Patents on Anti-Cancer Drug Discovery*. This year, Prof. KWOK received the 2017/2018 Best Teacher (Excellence in Service) award from the Faculty; and following support from the Deans, FHS Executive Committee and his colleagues, Prof. KWOK has successfully passed his early promotion evaluation and will be promoted to Associate Professor from 16 August 2018.



B-CAT MEETING #20

Prof. Wenhua ZHENG will give his talk at the upcoming B-CAT meeting on 20 June 2018.

